Viloxazine, sold under the brand name Qelbree and formerly as Vivalan[5] among others, is a selective norepinephrine reuptake inhibitor medication which is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.[1][6] It was marketed for almost 30years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD.[7][6][1] Viloxazine is taken orally.[1] It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form.[7][1]
Side effects of viloxazine include insomnia, headache, somnolence, fatigue, nausea, vomiting, decreased appetite, dry mouth, constipation, irritability, increased heart rate, and increased blood pressure.[1] Rarely, the medication may cause suicidal thoughts and behaviors.[1] It can also activate mania or hypomania in people with bipolar disorder.[1] Viloxazine acts as a selective norepinephrine reuptake inhibitor (NRI).[7][1][6] The immediate-release form has an elimination half-life of 2.5hours[7][2] while the half-life of the extended-release form is 7hours.[1]
Viloxazine was first described by 1972[8] and was marketed as an antidepressant in Europe in 1974.[7][9] It was not marketed in the United States at this time.[10] The medication was discontinued in 2002 for commercial reasons.[7][11][12] However, it was repurposed for the treatment of ADHD and was reintroduced, in the United States, in April 2021.[7][13][14] Viloxazine is a non-stimulant medication; it has no known misuse liability and is not a controlled substance.[1]
^ abcdefghijklmnop"Qelbree- viloxazine hydrochloride capsule, extended release". DailyMed. Archived from the original on 28 October 2022. Retrieved 3 May 2022.
^ abPinder RM, Brogden RN, Speight TM, Avery GS (June 1977). "Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness". Drugs. 13 (6): 401–421. doi:10.2165/00003495-197713060-00001. PMID 324751. S2CID 44804763.
^Case DE, Reeves PR (February 1975). "The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 5 (2): 113–129. doi:10.3109/00498257509056097. PMID 1154799.
^"SID 180462". PubChem Substance Summary. U.S. National Library of Medicine. Archived from the original on 14 June 2013. Retrieved 5 November 2005.
^Swiss Pharmaceutical Society (2000). Swiss Pharmaceutical Society (ed.). Index Nominum 2000: International Drug Directory. Taylor & Francis. pp. 1093–. ISBN 978-3-88763-075-1. Archived from the original on 2023-01-14. Retrieved 2022-05-03.
^ abcCutler AJ, Mattingly GW, Jain R, O'Neal W (April 2022). "Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents". CNS Spectrums. 27 (2): 199–207. doi:10.1017/S1092852920001984. PMID 33121553.
^ abcdefgFindling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, et al. (June 2021). "Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status". CNS Drugs. 35 (6): 643–653. doi:10.1007/s40263-021-00825-w. PMC 8219567. PMID 34003459.
^Cite error: The named reference pmid4558457 was invoked but never defined (see the help page).
^Cite error: The named reference OlivierSoudijn2000 was invoked but never defined (see the help page).
^Cite error: The named reference Dahmen was invoked but never defined (see the help page).
^Cite error: The named reference Williams was invoked but never defined (see the help page).
^Cite error: The named reference Cochrane2008 was invoked but never defined (see the help page).
^"Qelbree: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 2 April 2021. Retrieved 2 April 2021.
^"Supernus Announces FDA Approval of Qelbree (SPN-812) for the Treatment of ADHD". Supernus Pharmaceuticals (Press release). 2 April 2021. Archived from the original on 6 April 2021. Retrieved 3 April 2021.
Viloxazine, sold under the brand name Qelbree and formerly as Vivalan among others, is a selective norepinephrine reuptake inhibitor medication which is...
off-label to treat ADHD. Two non-stimulant medications, atomoxetine and viloxazine, are approved by the FDA and in other countries for the treatment of ADHD...
Teniloxazine (Lucelan, Metatone) – also a 5-HT2A receptor antagonist Viloxazine (Qelbree, formerly Vivalan) – also a 5-HT2B receptor antagonist and 5-HT2C...
with a specific indication for ADHD include atomoxetine (Strattera), viloxazine (Qelbree), guanfacine (Intuniv), and clonidine (Kapvay). Other medicines...
reuptake inhibitor, may be used off-label as an alternative to atomoxetine. Viloxazine, another selective norepinephrine reuptake inhibitor, was FDA-approved...
Global Information
(what is this?) (verify)